

DAFTAR PUSTAKA

- American Diabetes Association. (2024). 2. Diagnosis and Classification of Diabetes: Standards of Care in Diabetes—2024. *Diabetes Care*, 47(January), S20–S42. <https://doi.org/10.2337/dc24-S002>
- Annisa, Y., & Romdhoni, M. F. (2017). Perbandingan Resiko Terjadinya Retinopati Diabetik antara Pasien Hipertensi dan Non Hipertensi yang Mengidap Diabetes Mellitus di RSUD Majenang. *Medisains : Jurnal Ilmiah Ilmu-Ilmu Kesehatan*, 15(1), 31–38.
- Dang, D. H., Riaz, K. M., & Karamichos, D. (2022). Treatment of Non-Infectious Corneal Injury: Review of Diagnostic Agents, Therapeutic Medications, and Future Targets. *Drugs*, 82(2), 145–167. <https://doi.org/10.1007/s40265-021-01660-5>
- ES, H. S., Decroli, E., & Afriwardi, A. (2018). Faktor Risiko Pasien Nefropati Diabetik Yang Dirawat Di Bagian Penyakit Dalam Rsup Dr. M. Djamil Padang. *Jurnal Kesehatan Andalas*, 7(2), 149. <https://doi.org/10.25077/jka.v7i2.794>
- Fang, J., Luo, C., Zhang, D., He, Q., & Liu, L. (2023). Correlation between diabetic retinopathy and diabetic nephropathy: a two-sample Mendelian randomization study. *Frontiers in Endocrinology*, 14(November), 1–11. <https://doi.org/10.3389/fendo.2023.1265711>
- Farhani, F., Wahab, Z., & Tursinawati, Y. (2023). Hubungan antara Kadar HbA1c dan Derajat Retinopati Pasien Diabetes Melitus Tipe 2 di Rumah Sakit Mata Cicendo Bandung. *Jurnal Kesehatan Andalas*, 12(1), 15. <https://doi.org/10.25077/jka.v12i1.2157>
- Gupta, M., Rao, I. R., Nagaraju, S. P., Bhandary, S. V., Gupta, J., & Babu, G. T. C. (2022). Diabetic Retinopathy Is a Predictor of Progression of Diabetic Kidney Disease: A Systematic Review and Meta-Analysis. *International Journal of*

Nephrology, 2022. <https://doi.org/10.1155/2022/3922398>

Hung, C. C., Lin, H. Y. H., Hwang, D. Y., Kuo, I. C., Chiu, Y. W., Lim, L. M., Hwang, S. J., & Chen, H. C. (2017). Diabetic Retinopathy and Clinical Parameters Favoring the Presence of Diabetic Nephropathy could Predict Renal Outcome in Patients with Diabetic Kidney Disease /692/163/2743/137/138 /692/4022/1585/104/1586 /692/4022/1585/2759/1419 article. *Scientific Reports*, 7(1), 1–9. <https://doi.org/10.1038/s41598-017-01204-6>

Ikrima Rahmasari, E. S. W. (2019). Efektivitas Memordoca carantia (Pare) terhadap Penurunan Kadar Glukosa Darah. *Infokes*, 9(1), 57–64.

Imelda, S. I. (2019). Faktor-Faktor Yang Mempengaruhi Terjadinya diabetes Melitus di Puskesmas Harapan Raya Tahun 2018. *Scientia Journal*, 8(1), 28–39. <https://doi.org/10.35141/scj.v8i1.406>

Kemenkes RI. (2022). Penyakit Tidak Menular:Diabetes Fakta dan Angka. *Kementrian Kesehatan Republik Indonesia*, 1–2.

Khoury, C. C., Chen, S., & Ziyadeh, F. N. (2015). Pathophysiology of Diabetic Nephropathy. In *Chronic Renal Disease*. Elsevier Inc. <https://doi.org/10.1016/B978-0-12-411602-3.00013-5>

Kusdiyah, E., Makmur, M. J., & Aras, R. B. P. (2021). Karakteristik Faktor-Faktor Risiko Terjadinya Komplikasi Kronik Nefropati Diabetik Dan Atau Penyakit Pembuluh Darah Perifer Pada Penderita Diabetes Mellitus Di Rsud Raden Mattaher Tahun 2018. *Electronic Journal Scientific of Environmental Health And Disease*, 1(1). <https://doi.org/10.22437/eshad.v1i1.10761>

Lee, D. H. (2023). The Beneficial Effect of Glycemic Control against Adverse Outcomes in Patients with Tipe 2 Diabetes Mellitus and Chronic Kidney Disease. *Diabetes and Metabolism Journal*, 47(4), 484–486. <https://doi.org/10.4093/dmj.2023.0165>

- Lim, A. K. H. (2014). Diabetic nephropathy – Complications and treatment. *International Journal of Nephrology and Renovascular Disease*, 7, 361–381. <https://doi.org/10.2147/IJNRD.S40172>
- MacIsaac, R. J., Jerums, G., & Ekinci, E. I. (2018). Glycemic Control as Primary Prevention for Diabetic Kidney Disease. *Advances in Chronic Kidney Disease*, 25(2), 141–148. <https://doi.org/10.1053/j.ackd.2017.11.003>
- Marie. (2019). Diabetes Mellitus Diabetes Mellitus. *Ferri's Clinical Advisor 2020*, 512(58), 432–441. <https://www.msdmanuals.com/es-pe/hogar/trastornos-hormonales-y-metabólicos/diabetes-mellitus-y-otros-trastornos-del-metabolismo-de-la-glucosa-sanguínea/diabetes-mellitus>
- Meguro, S., Kabeya, Y., Tanaka, K., Kawai, T., Tomita, M., Katsuki, T., Oikawa, Y., Atsumi, Y., Shimada, A., Tanaka, M., Irie, J., Saisho, Y., & Itoh, H. (2014). Past obesity as well as present body weight status is a risk factor for diabetic nephropathy. *International Journal of Endocrinology*, 25. <https://doi.org/10.1155/2013/590569>
- Nasution, F., Andilala, & Azwar siregar, A. (2021). FAKTOR RISIKO KEJADIAN DIABETES MELLITUS (Risk Factors for The Event of Diabetes Mellitus). *Jurnal Ilmu Kesehatan*, 9, 94–102. http://scioteca.caf.com/bitstream/handle/123456789/1091/RED2017-Eng-8ene.pdf?sequence=12&isAllowed=y%0Ahttp://dx.doi.org/10.1016/j.regsciurbe.co.2008.06.005%0Ahttps://www.researchgate.net/publication/305320484_SYSTEM_PEMBETUNGAN_TERPUSAT_STRATEGI_MELESTARI
- Notoadmojo Soekidjo. (2010). *No Title*. Jakarta, IKAPI, 2005. <https://doi.org/->
- Perkeni, 2019. (2019). Pengelolaan Dan Pencegahan Diabetes Melitus Tipe 2 Dewasa di Indonesia. *PB Perkeni*, 133.
- Putri, R. N., & Waluyo, A. (2020). Faktor Resiko Neuropati Perifer Diabetik Pada

- Pasien Diabetes Melitus Tipe 2: Tinjauan Literatur. *Jurnal Keperawatan Abdurrah*, 3(1), 17–25. <https://doi.org/10.36341/jka.v3i2.839>
- Rahmawati, O., Wulan, D., Rengganis, S., Ilmu, B., Komunitas, K., Masyarakat, K., Kedokteran, F., & Lampung, U. (2022). Retinopati Diabetes Diabetic Retinopathy. *Agromedicine*, 9(1), 69–75.
- Rif'at, I. D., Hasneli N, Y., & Indriati, G. (2023). Gambaran Komplikasi Diabetes Melitus Pada Penderita Diabetes Melitus. *Jurnal Keperawatan Profesional*, 11(1), 52–69. <https://doi.org/10.33650/jkp.v11i1.5540>
- Sands, et al. (2019). *Association of Systolic and Diastolic Blood Pressure with Diabetic Retinopathy and Nephropathy. *Diabetes Care*. 9.* <https://doi.org/https://doi.org/10.2337/dc18-2410>
- Schoenberger, S. D., Kim, S. J., Shah, R., Sheng, J., & Cherney, E. (2014). Reduction of interleukin 8 and platelet-derived growth factor levels by topical ketorolac, 0.45%, in patients with diabetic retinopathy. *JAMA Ophthalmology*, 132(1), 32–37. <https://doi.org/10.1001/jamaophthalmol.2013.6203>
- Simatupang, A. (2019). Monografi Farmakologi Klinik Obat-Obat Diabetes Mellitus Tipe 2. In *Fk UKI* (Issue April). https://www.researchgate.net/publication/340730863_Monografi_Farmakologi_klinik_obat-obat_Diabetes_Mellitus_Tipe_2
- The Diabetic, R. C. N. R. (2015). Aflibercept, Bevacizumab, or Ranibizumab for Diabetic Macular Edema. *New England Journal of Medicine*, 372(13), 1193–1203. <https://doi.org/10.1056/nejmoa1414264>
- Ulfayani, N., & Haitam, M. (2023). Retinopati Diabetik: Patogenesis, Diagnosis, Tatalaksana Kini Dan Masa Depan. *Jurnal Klinik Dan Riset Kesehatan*, 3(1), 18–32. <https://doi.org/10.11594/jk-risk.03.1.4>

- Wang, W., & Lo, A. C. Y. (2018). Diabetic retinopathy: Pathophysiology and treatments. *International Journal of Molecular Sciences*, 19(6). <https://doi.org/10.3390/ijms19061816>
- Yulianti, T., & Anggraini, L. (2020). Faktor-Faktor yang Mempengaruhi Kepatuhan Pengobatan pada Pasien Diabetes Mellitus Rawat Jalan di RSUD Sukoharjo. *Pharmacon: Jurnal Farmasi Indonesia*, 17(2), 110–120. <https://doi.org/10.23917/pharmacon.v17i2.12261>